期刊文献+

1例肺炎合并横纹肌溶解症并发多脏器损害患儿的药学监护 被引量:1

Pharmaceutical Care of a Child with Pneumonia Complicated with Rhabdomyolysis and Multiple Organ Damage
原文传递
导出
摘要 目的探讨儿科临床药师在重症肺炎合并横纹肌溶解症并发急性多脏器功能损害治疗中的作用。方法临床药师对临床出现的1例横纹肌溶解症患儿诊疗过程中的治疗方案、不良反应和合并疾病对治疗的影响方面进行分析,并提出用药建议。结果参考临床药师意见,临床医师逐步完善了治疗,辨别药物不良反应,患儿病情好转出院。结论临床药师参与重症肺炎合并横纹肌溶解症患者的治疗过程,可协助医师完善用药方案,提高药物临床应用的合理性,保障患者用药安全。 OBJECTIVE To discuss the role of pediatric clinical pharmacists in the treatment of severe pneumonia complicated with rhabdomyolysis and acute rhabdomyolysis organ dysfunction. METHODS The clinical pharmacist analyzed the treatment plan, adverse reactions and the influence of comorbid diseases on the treatment of a child with rhabdomyolysis, and put forward medication recommendations. RESULTS With reference to the opinions of the clinical pharmacist, the clinician gradually improved the treatment and identified the adverse drug reactions.Eventually the child was discharged after improvement. CONCLUSION The participation of clinical pharmacists in the treatment of severe pneumonia patients with rhabdomyolysis can assist physicians to improve the medication plan, improve the rationality of clinical application of drugs, and ensure the safety of patients’ medication.
作者 毛心瑜 孙超 李三妮 尹雪冬 周志璇 邵祺晖 李志玲 MAO Xinyu;SUN Chao;LI Sanni;YIN Xuedong;ZHOU Zhixuan;SHAO Qihui;LI Zhiling(Shanghai Children’s Hospital,Children’s Hospital of Shanghai Jiao tong University,Shanghai 200062,China;Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Hebei Children’s Hospital,Shijiazhuang,Hebei 050031,China)
出处 《今日药学》 CAS 2021年第8期627-630,634,共5页 Pharmacy Today
基金 2020年上海交通大学医学院新型冠状病毒感染肺炎抗疫相关药事管理与合理用药研究专项课题(JDYX2020KYZX015)。
关键词 横纹肌溶解 药学监护 儿科 合理用药 rhabdomyolysis pharmaceutical care pediatrics rational drug use
  • 相关文献

参考文献6

二级参考文献75

  • 1朱艳兰.复方甘草酸苷致过敏性休克一例报告[J].青海医药杂志,2012,42(11):3-3. 被引量:1
  • 2陈业辉,胡建波,肖聪勤,杨柳平,黎伟龙.他克莫司致移植肾功能异常1例[J].中国新药与临床杂志,2005,24(1):45-46. 被引量:8
  • 3杨震坤,沈卫峰,张建盛,胡厚达.他克莫司致肥厚型心肌病一例[J].中华器官移植杂志,2005,26(2):102-102. 被引量:4
  • 4唐德斌.阿奇霉素与红霉素治疗小儿支原体肺炎的临床对比研究[J].临床肺科杂志,2006,11(4):545-546. 被引量:8
  • 5Katari SR, Mangnone M, Shapiro R, et al. Tacrolimus nephrotoxicity after renal transplantation [ J ]. Transplant Proc, 1997, 29(1- 2) :311.
  • 6Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. mulficenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group [ J ]. Transplantation, 1998, 66(12) : 1 736.
  • 7Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects [J]. Transplant Proc, 1999, 31(7A) :21s.
  • 8Wingard JR, Nash RA, Prepiorka D, et al. Relationship of tacrolimus (FK 506) whole blood concentrations and efficacy and safety after HLA - identical sibling bone marrow transplantation[J]. Biol Blood Marrow Transplant, 1998, 4 (3) : 157.
  • 9William FF. FK506 nephrotoxicity [ J ]. Renal Failure, 1999, 21:319.
  • 10Pirsch JD, Miller J, Deierhoi MH, et al. A comparion of tacrolimus (FK506)and cyclosporine for immunosuppression after cadaveric renal transplantation [ J ]. Transplantation, 1997, 63(7) :977.

共引文献201

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部